Ensysce Biosciences Inc ENSC

Alternate Symbol(s): ENSCW

Healthcare Biotechnology

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

NDAQ:ENSC - Post by User

Ensysce Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jan 31, 2024 11:00am

73 Views

Post# 35854906

(NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting

Breaking News: $ENSC (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting2024-01-31 09:03:48 ET DENVER, Colo., Jan. 31, 2023 ( www.247marketnews.com )- Ensysce Biosciences, Inc. (NASDAQ: ENSC) stated, this morning, that it completed a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead ‘Next Generation&#x...ENSC - (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market